Tertomotide hydrochloride

特托莫肽盐酸盐

Report date: 2026/02/24 20:00:16

Base Information

Drug NameTertomotide hydrochloride
Drug Alias NameTeloVachTERT RNA vaccine - KAEL-GemVaxTelomerase peptide vaccine - KAEL-GemVaxtertomotideRiavax +[7] 
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Synthetic peptide vaccine
Mechanisms of ActionImmunostimulantsImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsProstatic HyperplasiaNeurodegenerative DiseasesAlzheimer Disease +[7] 
Global Approved IndicationsPancreatic Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2014/09/15
Country/TerritoryBelgiumUnited StatesSweden +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPharmexa As
China Registration ClassN/A

Develop Information

Active CompaniesSamsung Pharmaceutical Co LtdGemvax & Kael
Inactive CompaniesKael-Gemvax Co LtdEarle A. Chiles Research InstitutePharmexa As +[4] 
Active IndicationsNeurodegenerative DiseasesAlzheimer DiseaseSupranuclear Palsy, Progressive +[4] 
Inactive IndicationsProstatic HyperplasiaCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular

Other Information

ATC CodeJ07X
Related LinksN/A